CHINA STAR ENT (00326) has released its interim results for the six months ended June 30, 2026, reporting a revenue of HK$95.314 million, a decrease of 62.84% year-on-year. The company recorded a loss attributable to owners of HK$56.094 million, narrowing by 49.41% compared to the same period last year, with a loss per share of 2.31 HK cents.

According to the announcement, the loss for the period primarily includes marketing, selling, and distribution expenses of HK$11.483 million (versus HK$35.214 million for the six months ended June 30, 2025), other operating expenses of HK$18.441 million (versus HK$45.734 million for the prior corresponding period), finance costs of HK$51.588 million (versus HK$51.868 million for the prior period), and administrative expenses of HK$58.505 million (versus HK$81.719 million for the prior period).

The narrowing of the loss was driven by an improved gross profit margin and an overall reduction in various expenses.